HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $25 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio has reiterated a Buy rating on Voyager Therapeutics (NASDAQ: VYGR) and maintained a price target of $25 for the stock.